

Suzanne C O'Neill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2366981/publications.pdf>

Version: 2024-02-01

35
papers

382
citations

840776

11
h-index

839539

18
g-index

35
all docs

35
docs citations

35
times ranked

622
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial. <i>Journal of Cancer Education</i> , 2023, 38, 292-300.	1.3	2
2	A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer. <i>Breast</i> , 2022, 61, 43-57.	2.2	9
3	Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis. <i>Psycho-Oncology</i> , 2022, 31, 788-797.	2.3	0
4	The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families. <i>Journal of Cancer Education</i> , 2021, 36, 72-84.	1.3	13
5	Facilitators of peer coaching/support engagement and dissemination among women at risk for and surviving with breast cancer. <i>Translational Behavioral Medicine</i> , 2021, 11, 153-160.	2.4	3
6	Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa114.	2.9	4
7	Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar. <i>Patient Education and Counseling</i> , 2021, 104, 250-256.	2.2	3
8	Physicians' perceptions of breast density notification laws and appropriate patient follow-up. <i>Breast Journal</i> , 2021, 27, 586-594.	1.0	3
9	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902.	1.6	7
10	Effect of a Randomized Trial of a Web-Based Intervention on Patient-Provider Communication About Breast Density. <i>Journal of Women's Health</i> , 2021, 30, 1529-1537.	3.3	0
11	Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, e1085-e1097.	2.9	11
12	Prior breast density awareness, knowledge, and communication in a health system-embedded behavioral intervention trial. <i>Cancer</i> , 2020, 126, 1614-1621.	4.1	8
13	Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. <i>Patient</i> , 2020, 13, 557-566.	2.7	2
14	Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial. , 2020, 24, 1-4.		4
15	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz062.	2.9	2
16	Cancer genetic health communication in families tested for hereditary breast/ovarian cancer risk: a qualitative investigation of impact on children's genetic health literacy and psychosocial adjustment. <i>Translational Behavioral Medicine</i> , 2019, 9, 493-503.	2.4	7
17	The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 417-427.	2.5	4
18	Between-Race Differences in Supplemental Breast Cancer Screening Before and After Breast Density Notification Law. <i>Journal of the American College of Radiology</i> , 2019, 16, 797-803.	1.8	12

#	ARTICLE	IF	CITATIONS
19	Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population. <i>Familial Cancer</i> , 2018, 17, 351-360.	1.9	13
20	Cost Effectiveness of Gene Expression Profile Testing in Community Practice. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-562.	1.6	35
21	Underuse of exon mutational analysis for gastrointestinal stromal tumors. <i>Journal of Surgical Research</i> , 2018, 231, 43-48.	1.6	4
22	Multilevel Influences on Patient-Oncologist Communication about Genomic Test Results: Oncologist Perspectives. <i>Journal of Health Communication</i> , 2018, 23, 679-686.	2.4	5
23	A web-based personalized risk communication and decision-making tool for women with dense breasts: Design and methods of a randomized controlled trial within an integrated health care system. <i>Contemporary Clinical Trials</i> , 2017, 56, 25-33.	1.8	14
24	Oncologist and organizational factors associated with variation in breast cancer multigene testing. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 167-176.	2.5	10
25	Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 549-555.	2.5	8
26	Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1216-1224.	4.9	17
27	Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years. <i>Cancer</i> , 2015, 121, 4062-4070.	4.1	21
28	Survey on Addressing the Information and Support Needs of Jewish Women at Increased Risk for or Diagnosed with Breast Cancer: The Sharsheret Experience. <i>Healthcare (Switzerland)</i> , 2015, 3, 324-337.	2.0	7
29	Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2015, 15, e83-e92.	2.4	7
30	Mammographic Breast Density as a Risk Factor for Breast Cancer: Awareness in a Recently Screened Clinical Sample. <i>Women's Health Issues</i> , 2014, 24, e321-e326.	2.0	29
31	Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-8.	1.1	14
32	The Front Line of Genomic Translation. <i>Journal of Cancer Epidemiology</i> , 2012, 2012, 1-3.	1.1	0
33	BRCA1/2 test results impact risk management attitudes, intentions, and uptake. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 755-764.	2.5	25
34	Primary care providers'™ willingness to recommend BRCA1/2 testing to adolescents. <i>Familial Cancer</i> , 2010, 9, 43-50.	1.9	18
35	Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2006, 142C, 251-259.	1.6	61